{"id":912393,"date":"2026-11-10T12:56:24","date_gmt":"2026-11-10T12:56:24","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/912393\/"},"modified":"2026-11-10T12:56:24","modified_gmt":"2026-11-10T12:56:24","slug":"eli-lilly-glp-1-pill-foundayo-helped-alleviate-sleep-apnea-studies-show","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/912393\/","title":{"rendered":"Eli Lilly GLP-1 pill Foundayo helped alleviate sleep apnea, studies show"},"content":{"rendered":"

Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter<\/a>, and co-hosts STAT\u2019s weekly biotech podcast, The Readout Loud<\/a>. You can reach Elaine on Signal at elaineywchen.70.<\/p>\n

Eli Lilly\u2019s GLP-1 pill Foundayo helped alleviate sleep apnea in two late-stage studies, but it doesn\u2019t appear as effective as Lilly\u2019s injectable drug Zepbound.<\/p>\n

In a one-year trial of patients who weren\u2019t receiving PAP therapy, a form of ventilation, those on Foundayo saw a reduction of 17.8 \u201cevents\u201d per hour on the apnea-hypopnea index (AHI), a measure of the number of times breathing stops and becomes restricted while sleeping. That compares with a reduction of 4.5 events among those on placebo.<\/p>\n

Additionally, 28% of treated patients achieved remission or mild disease, compared with 13% in the placebo group, according to data presented Monday at the annual meeting of the American Heart Association and published in JAMA<\/a>.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the pharma industry \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…\n","protected":false},"author":2,"featured_media":912394,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[58],"tags":[244,23714,48123,97,243,247,248],"class_list":["post-912393","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-biotechnology","tag-chronic-diseases","tag-eli-lilly","tag-health","tag-medication","tag-pharmaceuticals","tag-stat"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/912393","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=912393"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/912393\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/912394"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=912393"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=912393"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=912393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}